Enanta (ENTA) news
Recent news
Enanta 3Q loss/share 67c, est. loss/share 46c
AInvest Wire · Aug 10, 2026Enanta Pharmaceuticals: on track to report topline data from Phase 1 trial of EDP-978 in 4Q 2026
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that the first participant has been dosed in a Phase 1 clinical trial of EDP-978, an oral, once-daily KIT inhibitor in development for chronic urticaria and other mast cell-driven diseases. The Phase 1 trial is designed to evaluate the safety,…
AInvest Wire · Aug 10, 2026Enanta Pharmaceuticals Q3 net income USD -19.501 million
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) reported a net loss of $18.3 million for the fiscal third quarter ended June 30, 2025, representing loss of $0.85 per diluted common share . This reflects a slight improvement compared to the net loss of $22.7 million, or $1.07 per diluted share, in the…
AInvest Wire · Aug 10, 2026Enanta 3Q revenue $14.4M, estimate $16.9M
AInvest Wire · Aug 10, 2026Enanta Pharmaceuticals - enters open market sale agreement with Jefferies - SEC filing
AInvest Wire · Jul 2, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.